 |
Top 10 Liver Disease treatment startups
Updated: May 07, 2024 | Editor: Jason Kwon |
These startups develop new treatments and diagnostics technologies for fatty liver disease, nonalcoholic steatohepatitis (NASH), liver fibrosis and other liver diseases.
1
Country: USA | Funding: $3.7B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Country: USA | Funding: $1.5B
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
3
Country: USA | Funding: $951.1M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
4
Country: USA | Funding: $497M
Mirum Pharmaceuticals develops drugs for rare cholestatic liver diseases.
Mirum Pharmaceuticals develops drugs for rare cholestatic liver diseases.
5
Country: USA | Funding: $442.6M
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
6
Country: Belgium | Funding: $237M
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
7
Country: Switzerland | Funding: $184M
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
8
Country: USA | Funding: $173M
Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases.
Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases.
9
Country: Belgium | Funding: $149.1M
Promethera Biosciences is a biopharmaceutical company focused on cell therapy products to treat liver diseases.
Promethera Biosciences is a biopharmaceutical company focused on cell therapy products to treat liver diseases.
10
Country: France | Funding: €103.5M
ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.
ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.
11
Country: USA | Funding: $39M
Ocelot Bio brings new treatment options to patients with severe liver disease.
Ocelot Bio brings new treatment options to patients with severe liver disease.
12
Country: USA | Funding: $35M
Inipharm is building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease.
Inipharm is building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease.
13
Country: Switzerland | Funding: CHF21.1M
Versantis is a pharmaceutical company, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide.
Versantis is a pharmaceutical company, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide.
14
Country: India | Funding: $14M
Pandorum Technologies is a biotechnology startup with a distinct synergy of life science and engineering competences focused on tissue engineering. The company uses its proprietary technology platforms to design and manufacture functional, three-dimensional living human tissues; intended for medical research, therapeutic and other applications.
Pandorum Technologies is a biotechnology startup with a distinct synergy of life science and engineering competences focused on tissue engineering. The company uses its proprietary technology platforms to design and manufacture functional, three-dimensional living human tissues; intended for medical research, therapeutic and other applications.
15
Country: USA | Funding: $3M
In Diagnostics is developing next generation disposable lab-quality spectrophotometer that rely on digital microchips to analyze biological samples.
In Diagnostics is developing next generation disposable lab-quality spectrophotometer that rely on digital microchips to analyze biological samples.
16
Country: UK
Cyberliver is a company that focuses on delivering cutting edge solutions for liver care via use of innovative technology.
Cyberliver is a company that focuses on delivering cutting edge solutions for liver care via use of innovative technology.
17
Country: Canada
Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development headed by the team that enabled delivery for the world’s only approved small interfering RNA (siRNA)-LNP product, and an innovative culture that positions us to maintain our leadership for years to come.
Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development headed by the team that enabled delivery for the world’s only approved small interfering RNA (siRNA)-LNP product, and an innovative culture that positions us to maintain our leadership for years to come.
